Servier and Oncodesign Precision Medicine (OPM), specialized in precision medicine, announce that Servier has exercised its option to grant an exclusive license for their drug candidate, an inhibitor of the LRRK2 kinase target, which is the result of their collaboration on Parkinson’s disease.
In March 2019, Servier and OPM started a research and development collaboration on LRRK2 kinase inhibitors, as potential therapeutic agents for Parkinson’s disease. This collaboration is based on the complementary expertise of Servier and OPM in neurodegenerative diseases and kinase inhibitors. In June 2021, the two companies announced the selection of a preclinical drug candidate. Learn more
Servier expects to start a “Phase 1 study in healthy volunteers” before the end of 2022.
“The progress of the research and development program for this drug candidate in Parkinson’s disease is the result of the combined expertise of Servier and its partner Oncodesign. This collaboration reflects the Group’s commitment to focus its research on diseases with high medical needs, working closely with partners who share their know-how and technologies to create innovation synergies and accelerate the discovery of therapeutic solutions for the benefit of patients.”
Ross Jeggo, PhD, Global Head of Neuroscience and Immuno-Inflammation Therapeutic Area
More than 6.3 million people worldwide are affected by Parkinson’s disease (European Brain Council)